Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01507428 · OUTCOME

Relative Change in SUVpeak From the Baseline to the During-treatment Fludeoxyglucose F 18 (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) to LRPF With a 2-year Follow up. (ECOG-ACRIN)

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer · Source last updated 2026-04-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
percent change
Interval / dispersion
Standard Deviation
Time frame
Baseline to during-treatment (approximately between fractions 18-19) Randomization to 2 years

What was measured

To determine whether the relative change in SUVpeak (from the baseline to the during-treatment FDG-PET/CT) can predict the LRPF with a 2-year follow up. Relative ΔSUVpeak = (Mid-treatment SUVpeak - baseline SUVpeak)/baseline SUVpeak x 100 LRPF was determined from Randomization up to 2 years

Analysis population: All cases with both baseline and during-treatment FDG-PET/CT scans

Groups in this outcome

Standard Radiation Therapy

60 Gy radiation therapy in 30 once daily fractions concurrent with weekly carboplatin and paclitaxel. Baseline FDG-PET/CT scan within 4 weeks prior to registration During-RT FDG-PET/CT Scan between fractions 18 and 19

Adaptive Radiation Therapy

A maximum of 80.4 Gy radiation therapy in 30 once daily fractions concurrent with weekly carboplatin and paclitaxel. Radiation therapy dose is individualized for final 9 fractions based on imaging results from PET/CT scan between fractions 18 and 19. Baseline FDG-PET/CT scan within 4 weeks prior to registration During-RT FDG-PET/CT Scan between fractions 18 and 19

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Standard Radiation Therapy36
Adaptive Radiation Therapy71

Reported measurements

Source class 1
Values in percent change · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Standard Radiation Therapy-38.231.5Not reportedNot reportedNot reported
Adaptive Radiation Therapy-40.641.8Not reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. group Description
    The Wilcoxon Rank Sum Test was used to compare the Relative ΔSUVpeak (%) values between the standard and the treatment arms.
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.43
    statistical Method
    Wilcoxon (Mann-Whitney)
Complete source fields
analyses
  1. group Description
    The Wilcoxon Rank Sum Test was used to compare the Relative ΔSUVpeak (%) values between the standard and the treatment arms.
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.43
    statistical Method
    Wilcoxon (Mann-Whitney)
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        31.5
        value
        -38.2
      2. group Id
        OG001
        spread
        41.8
        value
        -40.6
denoms
  1. counts
    1. group Id
      OG000
      value
      36
    2. group Id
      OG001
      value
      71
    units
    Participants
description
To determine whether the relative change in SUVpeak (from the baseline to the during-treatment FDG-PET/CT) can predict the LRPF with a 2-year follow up. Relative ΔSUVpeak = (Mid-treatment SUVpeak - baseline SUVpeak)/baseline SUVpeak x 100 LRPF was determined from Randomization up to 2 years
dispersion Type
Standard Deviation
groups
  1. description
    60 Gy radiation therapy in 30 once daily fractions concurrent with weekly carboplatin and paclitaxel. Baseline FDG-PET/CT scan within 4 weeks prior to registration During-RT FDG-PET/CT Scan between fractions 18 and 19
    id
    OG000
    title
    Standard Radiation Therapy
  2. description
    A maximum of 80.4 Gy radiation therapy in 30 once daily fractions concurrent with weekly carboplatin and paclitaxel. Radiation therapy dose is individualized for final 9 fractions based on imaging results from PET/CT scan between fractions 18 and 19. Baseline FDG-PET/CT scan within 4 weeks prior to registration During-RT FDG-PET/CT Scan between fractions 18 and 19
    id
    OG001
    title
    Adaptive Radiation Therapy
param Type
MEAN
population Description
All cases with both baseline and during-treatment FDG-PET/CT scans
reporting Status
POSTED
time Frame
Baseline to during-treatment (approximately between fractions 18-19) Randomization to 2 years
title
Relative Change in SUVpeak From the Baseline to the During-treatment Fludeoxyglucose F 18 (FDG)-Positron Emission Tomography (PET)/Computed Tomography (CT) to LRPF With a 2-year Follow up. (ECOG-ACRIN)
type
PRIMARY
unit Of Measure
percent change

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice